gp120-Binding HIV-1 Antibodies for Broad Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapy (ART) is insufficient in reducing HIV-1 incidence and does not provide a functional cure due to the virus's ability to remain dormant in reservoirs, and existing vaccines fail to elicit effective neutralizing antibodies against HIV-1 due to genetic variation and high glycosylation of the envelope protein.
Innovation Solution
Development of an antigen binding site that specifically binds to HIV-1 viral envelope proteins, particularly gp120, with enhanced affinity and ability to neutralize the virus, competing with human broadly neutralizing antibodies and inhibiting binding of other antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to target HIV-1, then initial binding may occur, but the virus escapes antibody capture through genetic variation and mutation
Solution Approach 1:
The patent develops a pan-HIV-1 antibody (1842) that recognizes multiple HIV-1 clades (A through K) and variants by targeting conserved epitopes on the gp120 envelope protein. This universal binding capability allows the antibody to maintain effectiveness across genetically diverse viral strains, preventing viral escape through mutation.
Solution Approach 2:
The antibody is engineered to specifically recognize conserved regions of the HIV-1 gp120 envelope protein that are critical for viral function but resistant to mutation. By targeting these functionally constrained epitopes, the antibody maintains reliable binding while the virus cannot easily escape through genetic variation in these critical regions.
2Reliability
If existing antibodies are used for HIV-1 treatment, then some neutralization activity is achieved, but potency and breadth are insufficient against diverse strains
Solution Approach 1:
The patent employs antibody engineering techniques including CDR grafting, affinity maturation, and humanization to optimize the binding parameters of the anti-HIV-1 antibody. These modifications enhance the antibody's affinity, specificity, and neutralization potency while maintaining its ability to recognize diverse HIV-1 strains, achieving both high effectiveness and broad coverage.
3Reliability
If antiretroviral therapy is continued indefinitely, then viral load is suppressed, but treatment must continue for life due to dormant viral reservoirs
Solution Approach 1:
The patent develops a potent neutralizing antibody that can recognize and bind to HIV-1 particles including those from dormant reservoirs. This antibody serves as a therapeutic agent that can potentially clear residual virus from reservoirs, offering a path toward functional cure and enabling treatment interruption, thereby reducing the lifelong treatment duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antigen binding site effectively neutralizes HIV-1 with high specificity and potency, outperforming existing antibodies and reducing viral infectivity, while showing minimal binding to HIV-2.
Implementation Method 1
an antigen binding site that binds to or specifically binds to human immunodeficiency virus type 1 (HIV-1)... the antigen binding site is capable of neutralising or inhibiting HIV-1 infection... binds to a HIV-1 viral envelope protein, preferably the HIV-1 viral envelope protein is gp120
Data Source
AI summary
The invention relates to antigen binding sites, antibodies and fragments thereof, as well as compositions, kits and uses thereof for the treatment, attenuation and/or prevention of human immunodeficiency virus type 1 (HIV-1).